Mathers Edward T

Mathers Edward T has demonstrated a strong buying bias across multiple biotech and pharmaceutical companies, with $20 million in total purchases compared to just $27,627 in sales across 29 transactions. The most significant recent activity includes a $15 million acquisition of SGP shares on February 9, 2026, followed by two large purchases of KRRO stock totaling nearly $5 million on March 10, 2026. These acquisitions dwarf the modest selling activity, which primarily involved small dispositions of NEUE shares in October 2025 totaling approximately $27,627. The pattern shows concentrated buying in SGP and KRRO alongside minor administrative transactions in RYTM (March 2026) and OKUR (December 2025) with no reported dollar value. The trading history reveals a clear preference for accumulating positions rather than liquidating them, with recent activity skewing heavily toward purchases. While the NEUE transactions in late 2025 included some sales and option exercises, these were relatively insignificant compared to the subsequent multi-million dollar investments in SGP and KRRO. The absence of any material selling in these newer positions suggests a continued bullish outlook on these holdings. All transactions occurred within a concentrated timeframe, with the most substantial activity clustered between February and March 2026 across three primary tickers: SGP, KRRO, and RYTM.